251 related articles for article (PubMed ID: 31619387)
1. BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
Kanakkanthara A; Kurmi K; Ekstrom TL; Hou X; Purfeerst ER; Heinzen EP; Correia C; Huntoon CJ; O'Brien D; Wahner Hendrickson AE; Dowdy SC; Li H; Oberg AL; Hitosugi T; Kaufmann SH; Weroha SJ; Karnitz LM
Cancer Res; 2019 Dec; 79(23):5920-5929. PubMed ID: 31619387
[TBL] [Abstract][Full Text] [Related]
2. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
[TBL] [Abstract][Full Text] [Related]
3. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
Paculová H; Kramara J; Šimečková Š; Fedr R; Souček K; Hylse O; Paruch K; Svoboda M; Mistrík M; Kohoutek J
Tumour Biol; 2017 Oct; 39(10):1010428317727479. PubMed ID: 29025359
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
[TBL] [Abstract][Full Text] [Related]
7. Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.
Kanska J; Aspuria PP; Taylor-Harding B; Spurka L; Funari V; Orsulic S; Karlan BY; Wiedemeyer WR
Oncotarget; 2017 Apr; 8(16):26200-26220. PubMed ID: 28412735
[TBL] [Abstract][Full Text] [Related]
8. Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
Li J; Yue H; Yu H; Lu X; Xue X
BMC Cancer; 2021 Jan; 21(1):67. PubMed ID: 33446144
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP
J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047
[TBL] [Abstract][Full Text] [Related]
10. ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer.
Kanakkanthara A; Huntoon CJ; Hou X; Zhang M; Heinzen EP; O'Brien DR; Oberg AL; John Weroha S; Kaufmann SH; Karnitz LM
Nat Commun; 2019 Oct; 10(1):4632. PubMed ID: 31604914
[TBL] [Abstract][Full Text] [Related]
11.
Kraya AA; Maxwell KN; Eiva MA; Wubbenhorst B; Pluta J; Feldman M; Nayak A; Powell DJ; Domchek SM; Vonderheide RH; Nathanson KL
JCO Precis Oncol; 2022 Feb; 6():e2100159. PubMed ID: 35201851
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance.
Hu B; Guo Y
Biochem Biophys Res Commun; 2019 Feb; 509(2):373-378. PubMed ID: 30591219
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
14. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
15. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
Stewart J; George A; Banerjee S
Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
[TBL] [Abstract][Full Text] [Related]
17. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ivy SP; Kunos CA; Arnaldez FI; Kohn EC
Expert Opin Investig Drugs; 2019 Sep; 28(9):771-785. PubMed ID: 31449760
[No Abstract] [Full Text] [Related]
18. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
[TBL] [Abstract][Full Text] [Related]
19. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
20. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]